96 Tests PN: B115320

Components:

45x Ab-conjugated beads (S5P7 - human PAI-1/Serpin E1 -bead). PN: B115320A. One vial containing 100 µL of anti-human PAI-1/Serpin E1 conjugated to AimPlex Bead S5P7.

25x Biotin-detection Ab (human PAI-1/Serpin E1 Biotin-dAb). PN: B115320B. One vial containing 100 µL of biotinylated anti-human PAI-1/Serpin E1.

Lyophilized Standard - Human PAI-1/Serpin E1. PN: B115320S. One vial containing lyophilized PAI-1/Serpin E1.

Storage:  2-8 C in the dark.

Important: Sodium azide forms explosive compounds with heavy metals. These products contain <0.05% (w/w) azide which with repeated contact with lead and copper commonly found in plumbing drains may result in the buildup of shock sensitive compounds. Dispose in accordance with regulations from your institute.

Application: Optimal antibody pair and antigen standard for assaying human PAI-1/Serpin E1. To be used in conjunction with the AimPlex NR Basic Kit (PN: P100001) and a diluent kit. Refer to the AimPlex Multiplex Immunoassay User Manual and kit inserts for the assay procedure.

For Research Use Only.  Not for use in diagnostic procedures.

Assay Specifications:

  • Sample types: Cell culture supernatant, plasma, bodily fluid and tissue/cell lysate

  • Sensitivity (LOD): < 50 pg/mL

  • Quantitation range:

  • LLOQ: < 100 pg/mL

  • ULOQ: > 50,000 pg/mL

  • Standard dose recovery: 70-130%

  • Intra-assay CV: < 10%

  • Inter-assay CV: < 20%

  • Sample volume: 15 µL/test

Description:

Plasminogen activator inhibitor-1 (PAI-1) also known as endothelial plasminogen activator inhibitor or serpin E1 is a risk factor for thrombosis and atherosclerosis. PAI-1's main function is the inhibition of urokinase plasminogen activator (uPA), an enzyme responsible for the cleavage of plasminogen to form plasmin.  It is an inhibitor of fibrinolysis, the physiological process that degrades blood clots. PAI-1 is present in increased levels in various disease such as cancer, as well as in obesity and the metabolic syndrome. It has been linked to the increased occurrence of thrombosis in patients with these conditions.

References:

1.    Vaughan DE.  PAI-1 and atherothrombosis. Journal of Thrombosis and Haemostasis. 2005, 3 (8): 1879–83. doi:10.1111/j.1538-7836.2005.01420.x. PMID 16102055. S2CID 6651339.

2.    Zheng M, et al. Hepatic stellate cell senescence in liver fibrosis: Characteristics, mechanisms and perspectives. Mechanisms of Ageing and Development. 2021, 199: 111572. doi:10.1016/j.mad.2021.111572. PMID 34536446.